Gossamer Bio Files 8-K on Financials
Ticker: GOSS · Form: 8-K · Filed: May 15, 2025 · CIK: 1728117
| Field | Detail |
|---|---|
| Company | Gossamer Bio, Inc. (GOSS) |
| Form Type | 8-K |
| Filed Date | May 15, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Gossamer Bio dropped an 8-K on financials, check it for the latest numbers.
AI Summary
Gossamer Bio, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with no specific financial figures or operational details provided in this initial report.
Why It Matters
This 8-K filing indicates Gossamer Bio is providing an update on its financial condition and operational results to the SEC and investors.
Risk Assessment
Risk Level: low — This is a routine filing reporting on financial condition and operations, not indicating any immediate adverse events.
Key Players & Entities
- Gossamer Bio, Inc. (company) — Registrant
- May 15, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- San Diego, California (location) — Principal Executive Offices
FAQ
What specific financial results are being reported by Gossamer Bio?
The filing indicates reporting on 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific figures are not detailed in the provided text.
When was this 8-K filing submitted?
The filing was submitted on May 15, 2025.
What is Gossamer Bio's principal business address?
Gossamer Bio's principal executive offices are located at 3115 Merryfield Row, Suite 120, San Diego, California, 92121.
What is the exact name of the company filing this report?
The exact name of the registrant is Gossamer Bio, Inc.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 15, 2025 regarding Gossamer Bio, Inc. (GOSS).